RT Journal Article
SR Electronic
T1 Life course exposures continually shape antibody profile and risk of seroconversion to influenza
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.15.19015693
DO 10.1101/2020.01.15.19015693
A1 Yang, Bingyi
A1 Lessler, Justin
A1 Zhu, Huachen
A1 Jiang, Chao Qiang
A1 Read, Jonathan M.
A1 Hay, James A.
A1 Kwok, Kin On
A1 Shen, Ruiyin
A1 Guan, Yi
A1 Riley, Steven
A1 Cummings, Derek A.T.
YR 2020
UL http://medrxiv.org/content/early/2020/01/16/2020.01.15.19015693.abstract
AB Complex exposure histories and immune mediated interactions between influenza strains contribute to the life course of human immunity to influenza. Antibody profiles can be generated by characterizing immune responses to multiple antigenically variant strains, but how these profiles vary across individuals and determine future responses is unclear. We used hemagglutination inhibition titers from 21 H3N2 strains to construct 777 paired antibody profiles from people aged 2 to 86, and developed novel metrics to capture features of these profiles. Total antibody titer per potential influenza exposure increases in early life, then decreases in middle age. Increased titers to one or more strains were seen in 97.8% of participants, suggesting widespread influenza exposure. While titer changes were seen to all strains, recently circulating strains exhibited the greatest variation. Higher pre-existing, homologous titers reduced the risk of seroconversion to recent strains. After adjusting for homologous titer, we also found an increased frequency of seroconversion among those with higher immunity to older previously exposed strains. Our results suggest that a comprehensive quantitative description of immunity encompassing past exposures could lead to improved correlates of risk of influenza.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the NIH R56AG048075 (D.A.T.C., J.L.), NIH R01AI114703 (D.A.T.C., B.Y.), the Wellcome Trust 200861/Z/16/Z (S.R.) and 200187/Z/15/Z (S.R.). D.A.T.C., J.M.R. and S.R. acknowledge support from the National Institutes of Health Fogarty Institute (R01TW0008246). J.M.R. acknowledges support from the Medical Research Council (MR/S004793/1) and the Engineering and Physical Sciences Research Council (EP/N014499/1).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data and code to reproduce the study findings will be available at (https://github.com/UF-IDD/Fluscape_Paired_Serology). https://github.com/UF-IDD/Fluscape_Paired_Serology